Portfolio Holdings Detail for ISIN IE000X08RX14
| Stock Name / Fund | iShares MSCI World ESG Enhanced UCITS ETF NZD Hedged (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | EDMNZx(NZD) CXE |
Holdings detail for NBIX
| Stock Name | Neurocrine Biosciences Inc |
| Ticker | NBIX(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US64125C1099 |
| LEI | 549300FECER0XBN49756 |
Show aggregate NBIX holdings
News associated with NBIX
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by M&T Bank Corp
- M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,978 shares of the company’s stock after buying an additional 1,322 shares during the quarter. […] - 2025-03-12 08:19:05
- Victory Capital Management Inc. Sells 14,309 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Victory Capital Management Inc. decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 189,896 shares of the company’s stock after selling 14,309 shares during the period. Victory Capital Management […] - 2025-03-11 08:16:52
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Charles Schwab Investment Management Inc.
- Charles Schwab Investment Management Inc. raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 762,557 shares of the company’s stock after buying an additional 15,266 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Neurocrine Biosciences were worth $104,089,000 as […] - 2025-03-10 11:50:03
- Smartleaf Asset Management LLC Grows Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Smartleaf Asset Management LLC lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 37.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 538 shares of the company’s stock after purchasing an additional 146 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Neurocrine Biosciences were worth $74,000 as of its […] - 2025-03-10 09:10:55
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by IFP Advisors Inc
- IFP Advisors Inc raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,020 shares of the company’s stock after purchasing an additional 137 shares during the period. IFP Advisors Inc’s holdings […] - 2025-03-03 09:35:15
- First Horizon Advisors Inc. Has $118,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- First Horizon Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 14.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 865 shares of the company’s stock after selling 142 shares during the period. First Horizon Advisors Inc.’s holdings in Neurocrine Biosciences were worth $118,000 at the end […] - 2025-02-27 09:05:01
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Vontobel Holding Ltd.
- Vontobel Holding Ltd. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 42.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,442 shares of the company’s stock after selling 6,148 shares during the period. Vontobel Holding […] - 2025-02-19 09:15:16
- Neurocrine Biosciences (NASDAQ:NBIX) Earns Hold Rating from Analysts at Deutsche Bank Aktiengesellschaft
- Deutsche Bank Aktiengesellschaft initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report published on Tuesday, MarketBeat reports. The brokerage issued a hold rating and a $138.00 target price on the stock. NBIX has been the subject of a number of other research reports. Needham & Company LLC restated a “hold” […] - 2025-02-14 09:04:49
- State of Alaska Department of Revenue Cuts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- State of Alaska Department of Revenue cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,535 shares of the company’s stock after selling 200 shares during the quarter. State of Alaska Department […] - 2025-02-12 10:44:45
- Brokerages Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $169.20
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-three research firms that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on […] - 2025-02-12 08:12:57
- Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $163.00 at Guggenheim
- Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock. NBIX has been the subject of several other research reports. Royal Bank of Canada decreased their price target on Neurocrine Biosciences from […] - 2025-02-11 07:12:48
- Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 4.9% After Analyst Downgrade
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report)’s share price traded down 4.9% on Monday after Guggenheim lowered their price target on the stock from $165.00 to $163.00. Guggenheim currently has a buy rating on the stock. Neurocrine Biosciences traded as low as $116.48 and last traded at $116.60. 1,568,535 shares changed hands during mid-day […] - 2025-02-11 06:10:42
- Royal Bank of Canada Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $148.00
- Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $154.00 to $148.00 in a report released on Friday,Benzinga reports. The brokerage currently has a sector perform rating on the stock. A number of other research firms have also recently weighed in on NBIX. Canaccord Genuity Group lowered […] - 2025-02-10 16:58:49
- Canaccord Genuity Group Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $163.00
- Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective trimmed by Canaccord Genuity Group from $172.00 to $163.00 in a research note published on Friday,Benzinga reports. The firm currently has a buy rating on the stock. Other analysts have also recently issued research reports about the stock. Raymond James restated an “outperform” rating and […] - 2025-02-10 16:58:47
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by abrdn plc
- abrdn plc boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 14.8% during the fourth quarter, Holdings Channel reports. The firm owned 156,574 shares of the company’s stock after buying an additional 20,150 shares during the quarter. abrdn plc’s holdings in Neurocrine Biosciences were worth $21,372,000 at the end of […] - 2025-02-07 09:28:53
- Notable ETF Outflow Detected - XBI, NBIX, ALNY, UTHR
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $76.4 million dollar outflow -- that's a 1.2% decrease week over week ( - 2025-02-05 16:06:35
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Tokio Marine Asset Management Co. Ltd.
- Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,183 shares of the company’s stock after selling 119 shares […] - 2025-02-05 10:54:50
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Robeco Institutional Asset Management B.V.
- Robeco Institutional Asset Management B.V. decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 96.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,634 shares of the company’s stock after selling 372,648 shares during the period. Robeco Institutional Asset Management […] - 2025-02-04 08:47:05
- KBC Group NV Has $1.96 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- KBC Group NV lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 24.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 14,330 shares of the company’s stock after selling 4,642 shares during the period. KBC Group NV’s holdings in Neurocrine Biosciences were […] - 2025-02-02 11:40:51
iShares MSCI World ESG Enhanced UCITS ETF NZD Hedged (Acc) NBIX holdings
| Date | Number of NBIX Shares Held | Base Market Value of NBIX Shares | Local Market Value of NBIX Shares | Change in NBIX Shares Held | Change in NBIX Base Value | Current Price per NBIX Share Held | Previous Price per NBIX Share Held |
|---|
| 2024-11-08 (Friday) | 2,856 | USD 359,113 | USD 359,113 | 0 | USD 5,026 | USD 125.74 | USD 123.98 |
| 2024-11-07 (Thursday) | 2,856 | USD 354,087 | USD 354,087 | 0 | USD -3,770 | USD 123.98 | USD 125.3 |
| 2024-11-06 (Wednesday) | 2,856 | USD 357,857 | USD 357,857 | 0 | USD 10,767 | USD 125.3 | USD 121.53 |
| 2024-11-05 (Tuesday) | 2,856 | USD 347,090 | USD 347,090 | 0 | USD 2,856 | USD 121.53 | USD 120.53 |
| 2024-11-04 (Monday) | 2,856 | USD 344,234 | USD 344,234 | 0 | USD -4,798 | USD 120.53 | USD 122.21 |
| 2024-11-01 (Friday) | 2,856 | USD 349,032 | USD 349,032 | -48 | USD -232 | USD 122.21 | USD 120.27 |
| 2024-10-31 (Thursday) | 2,904 | USD 349,264 | USD 349,264 | 0 | USD -11,790 | USD 120.27 | USD 124.33 |
| 2024-10-30 (Wednesday) | 2,904 | USD 361,054 | USD 361,054 | 0 | USD 23,638 | USD 124.33 | USD 116.19 |
| 2024-10-29 (Tuesday) | 2,904 | USD 337,416 | USD 337,416 | 0 | USD -29 | USD 116.19 | USD 116.2 |
| 2024-10-28 (Monday) | 2,904 | USD 337,445 | USD 337,445 | 0 | USD 349 | USD 116.2 | USD 116.08 |
| 2024-10-25 (Friday) | 2,904 | USD 337,096 | USD 337,096 | 0 | USD 1,626 | USD 116.08 | USD 115.52 |
| 2024-10-24 (Thursday) | 2,904 | USD 335,470 | USD 335,470 | 0 | USD 1,278 | USD 115.52 | USD 115.08 |
| 2024-10-23 (Wednesday) | 2,904 | USD 334,192 | USD 334,192 | 0 | USD -4,937 | USD 115.08 | USD 116.78 |
| 2024-10-22 (Tuesday) | 2,904 | USD 339,129 | USD 339,129 | 0 | USD 610 | USD 116.78 | USD 116.57 |
| 2024-10-21 (Monday) | 2,904 | USD 338,519 | USD 338,519 | 0 | USD -4,182 | USD 116.57 | USD 118.01 |
| 2024-10-18 (Friday) | 2,904 | USD 342,701 | USD 342,701 | | | | |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of NBIX by Blackrock for IE000X08RX14
Show aggregate share trades of NBIX| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2024-11-01 | SELL | -48 | | | 122.210* | | 117.45 Profit of 5,637 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of NBIX
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-03-12 | 201,638 | 171 | 467,323 | 43.1% |
| 2025-03-11 | 231,365 | 248 | 763,188 | 30.3% |
| 2025-03-10 | 214,090 | 558 | 359,059 | 59.6% |
| 2025-03-07 | 251,531 | 5,013 | 472,743 | 53.2% |
| 2025-03-06 | 224,166 | 21 | 423,941 | 52.9% |
| 2025-03-05 | 159,715 | 4,490 | 349,122 | 45.7% |
| 2025-03-04 | 307,911 | 358 | 727,572 | 42.3% |
| 2025-03-03 | 222,563 | 96 | 471,074 | 47.2% |
| 2025-02-28 | 237,037 | 493 | 383,823 | 61.8% |
| 2025-02-27 | 211,618 | 246 | 374,160 | 56.6% |
| 2025-02-26 | 220,080 | 241 | 366,566 | 60.0% |
| 2025-02-25 | 272,363 | 1 | 561,032 | 48.5% |
| 2025-02-24 | 365,205 | 3,840 | 564,433 | 64.7% |
| 2025-02-21 | 445,671 | 334 | 788,129 | 56.5% |
| 2025-02-20 | 243,050 | 438 | 387,174 | 62.8% |
| 2025-02-19 | 169,781 | 1,293 | 322,572 | 52.6% |
| 2025-02-18 | 243,796 | 157 | 366,506 | 66.5% |
| 2025-02-14 | 365,651 | 87,819 | 568,416 | 64.3% |
| 2025-02-13 | 289,466 | 152 | 469,422 | 61.7% |
| 2025-02-12 | 465,393 | 133 | 906,486 | 51.3% |
| 2025-02-11 | 368,843 | 1,974 | 1,121,402 | 32.9% |
| 2025-02-10 | 522,039 | 4,104 | 1,171,936 | 44.5% |
| 2025-02-07 | 1,463,105 | 27,927 | 2,810,843 | 52.1% |
| 2025-02-06 | 179,102 | 0 | 518,198 | 34.6% |
| 2025-02-05 | 205,664 | 45,247 | 651,449 | 31.6% |
| 2025-02-04 | 103,885 | 1,664 | 235,641 | 44.1% |
| 2025-02-03 | 146,736 | 35,322 | 317,012 | 46.3% |
| 2025-01-31 | 124,777 | 3,388 | 285,060 | 43.8% |
| 2025-01-30 | 181,573 | 5,230 | 306,225 | 59.3% |
| 2025-01-29 | 190,973 | 4,394 | 370,055 | 51.6% |
| 2025-01-28 | 169,019 | 21,990 | 434,350 | 38.9% |
| 2025-01-27 | 200,565 | 4,721 | 492,244 | 40.7% |
| 2025-01-24 | 229,526 | 401 | 325,978 | 70.4% |
| 2025-01-23 | 139,412 | 200 | 216,422 | 64.4% |
| 2025-01-22 | 122,562 | 417 | 305,099 | 40.2% |
| 2025-01-21 | 258,260 | 399 | 455,791 | 56.7% |
| 2025-01-17 | 170,177 | 1,841 | 321,061 | 53.0% |
| 2025-01-16 | 150,036 | 41 | 322,102 | 46.6% |
| 2025-01-15 | 175,532 | 83 | 291,445 | 60.2% |
| 2025-01-14 | 219,002 | 6,927 | 417,631 | 52.4% |
| 2025-01-13 | 265,341 | 3,829 | 432,476 | 61.4% |
| 2025-01-10 | 290,116 | 12,745 | 427,351 | 67.9% |
| 2025-01-08 | 123,321 | 90 | 273,321 | 45.1% |
| 2025-01-07 | 147,606 | 3,695 | 340,258 | 43.4% |
| 2025-01-06 | 183,685 | 354 | 352,352 | 52.1% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.